-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Neutral on Bicara Therapeutics, Raises Price Target to $20

Benzinga·08/12/2026 13:17:59
Listen to the news
Mizuho analyst Joseph Catanzaro maintains Bicara Therapeutics (NASDAQ:BCAX) with a Neutral and raises the price target from $18 to $20.